EyePoint (EYPT) Panoramica del titolo
EyePoint, Inc. è impegnata nello sviluppo e nella commercializzazione di farmaci per migliorare la vita dei pazienti affetti da gravi malattie della retina. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 1/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
+ 1 più rischio
EYPT Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di EyePoint, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$3.85 |
| Massimo di 52 settimane | US$19.11 |
| Minimo di 52 settimane | US$3.42 |
| Beta | 1.64 |
| Variazione di 1 mese | -27.63% |
| Variazione a 3 mesi | -73.23% |
| Variazione di 1 anno | -71.18% |
| Variazione a 3 anni | -52.05% |
| Variazione a 5 anni | -66.40% |
| Variazione dall'IPO | -87.82% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
EYPT: Second Phase 3 Wet AMD Readout Will Reshape 2026 Upside Potential
EyePoint's updated analyst price targets have moved sharply lower into the single digits from prior levels. Analysts are responding to the failed Phase 3 LUGANO study, growing regulatory uncertainty around Duravyu in wet age-related macular degeneration, and a shift toward more cautious assumptions, despite supportive views on secondary endpoints from some firms.Seeking Alpha • Aug 27
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
Summary EyePoint is rated a speculative strong buy, with a revised fair value of $19 per share, despite increased regulatory risk after LUGANO’s primary endpoint miss. LUGANO lowered estimated wet-AMD approval probability to 30%, but its strong durability results reinforced DURAVYU’s competitive and commercial potential. LUGANO’s primary endpoint miss appears largely driven by unusually unfavorable circumstances, supporting an estimated 70–75% chance that LUCIA meets its primary endpoint. DCF valuation assumes 15% penetration among treatment-naïve wet-AMD patients and 2% annual switching, with DME contributing nearly half of EYPT’s risk-adjusted value. Current valuation offers substantial compensation for binary risk, with a 70% chance EYPT’s fair value is at least $14 per share and a 20% chance of a $51 scenario. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 17
EYPT: Upcoming LUCIA Phase 3 Readout Will Drive Sentiment Reset
Analysts have cut their average EyePoint fair value estimate from $20.00 to $8.00 after the Duravyu LUGANO Phase 3 miss, citing reduced revenue growth expectations, a slightly higher discount rate, and a much higher assumed future P/E multiple, despite modestly stronger projected profit margins. Analyst Commentary Recent research on EyePoint highlights a clear shift in tone after the Duravyu LUGANO Phase 3 miss.Recent updates
Aggiornamento narrativa • Sep 03
EYPT: Second Phase 3 Wet AMD Readout Will Reshape 2026 Upside Potential
EyePoint's updated analyst price targets have moved sharply lower into the single digits from prior levels. Analysts are responding to the failed Phase 3 LUGANO study, growing regulatory uncertainty around Duravyu in wet age-related macular degeneration, and a shift toward more cautious assumptions, despite supportive views on secondary endpoints from some firms.Seeking Alpha • Aug 27
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
Summary EyePoint is rated a speculative strong buy, with a revised fair value of $19 per share, despite increased regulatory risk after LUGANO’s primary endpoint miss. LUGANO lowered estimated wet-AMD approval probability to 30%, but its strong durability results reinforced DURAVYU’s competitive and commercial potential. LUGANO’s primary endpoint miss appears largely driven by unusually unfavorable circumstances, supporting an estimated 70–75% chance that LUCIA meets its primary endpoint. DCF valuation assumes 15% penetration among treatment-naïve wet-AMD patients and 2% annual switching, with DME contributing nearly half of EYPT’s risk-adjusted value. Current valuation offers substantial compensation for binary risk, with a 70% chance EYPT’s fair value is at least $14 per share and a 20% chance of a $51 scenario. Read the full article on Seeking AlphaAggiornamento narrativa • Aug 17
EYPT: Upcoming LUCIA Phase 3 Readout Will Drive Sentiment Reset
Analysts have cut their average EyePoint fair value estimate from $20.00 to $8.00 after the Duravyu LUGANO Phase 3 miss, citing reduced revenue growth expectations, a slightly higher discount rate, and a much higher assumed future P/E multiple, despite modestly stronger projected profit margins. Analyst Commentary Recent research on EyePoint highlights a clear shift in tone after the Duravyu LUGANO Phase 3 miss.
Aggiornamento narrativa • Jul 23
EYPT: Phase 3 Retinal Readouts In 2026 Will Drive Bullish Repricing
EyePoint's updated analyst price target of $66.28, compared with the prior $59.30 fair value estimate, reflects analysts' focus on upcoming Phase 3 Duravyu readouts in wet AMD and DME and the potential for these large retinal markets, along with differing views on near term pricing ranging from $30 to $65 per share. Analyst Commentary Recent Street research on EyePoint highlights a wide spread in price targets but a generally constructive tone around the upcoming Duravyu Phase 3 readouts in wet age related macular degeneration and diabetic macular edema.Aggiornamento narrativa • Jul 09
EYPT: Phase 3 Retinal Data Will Drive Bullish 2026 Upside
EyePoint's updated analyst price target has moved from $37.00 to about $40.54, with analysts pointing to upcoming Phase 3 DURAVYU data in wet AMD and the large combined wet AMD and DME market opportunity as key supports for the higher valuation range. Analyst Commentary Recent Street research on EyePoint highlights a mix of optimism around the DURAVYU program and the size of the retinal disease market, while still leaving room for questions on execution and risk around the upcoming Phase 3 readouts.Aggiornamento narrativa • Jun 25
EYPT: Phase 3 Wet AMD Trials Will Support Bullish 2026 Upside
Analysts have reiterated their $37.00 price target on EyePoint, citing updated assumptions around very large revenue growth, a profit margin near 19.6% and a forward P/E of about 65.6x as support for keeping the valuation framework broadly unchanged. What's in the News for EyePoint The Independent Data Safety Monitoring Committee completed its third scheduled review of EyePoint's pivotal Phase 3 program for DURAVYU in wet age-related macular degeneration and recommended that the LUGANO and LUCIA trials continue as planned with no protocol changes.Aggiornamento narrativa • Jun 05
EYPT: Phase 3 Wet AMD Readouts In 2026 Will Drive Future Upside
Analysts have raised EyePoint's price target to $35 from $31, reflecting updated assumptions about significant early revenue growth, slightly higher profit margin expectations, and a lower anticipated future P/E multiple. What's in the News EyePoint is approaching top-line data from its pivotal Phase 3 DURAVYU trials for wet age-related macular degeneration, with the first readout expected to begin in August 2026 and a second pivotal readout about two months later, according to recent news reports.Aggiornamento narrativa • May 20
EYPT: Phase 3 Eye Disease Program Will Drive Future Upside Potential
Narrative Update on EyePoint Analysts have adjusted the average price target on EyePoint to $37.00 from $37.17. This change reflects recent upward target revisions into the $29 to $35 range as they consider updated Q4 results, progress on Duravyu programs, and the inclusion of the Phase 3 diabetic macular edema program in their valuation work.Aggiornamento narrativa • May 04
EYPT: Phase 3 DME Pivotal Program Will Drive Future Upside Potential
Analysts have raised EyePoint's average price target by $6, from $29 to $35, citing updated post-Q4 estimates, the inclusion of the Phase 3 diabetic macular edema program in valuation, and refreshed views on the Duravyu programs. Analyst Commentary Recent Street research reflects a more constructive stance on EyePoint, with several firms updating their valuation frameworks after the Q4 report and program updates.Aggiornamento narrativa • Apr 19
EYPT: Phase 3 Diabetic Macular Edema Program Will Underpin Future Upside Potential
Narrative update on EyePoint The fair value estimate for EyePoint edges down slightly to $37.17 from $37.42, even as analysts lift published price targets to a range of $29 to $35. They cite updated models after Q4 results, inclusion of the Phase 3 diabetic macular edema program, and refreshed assumptions around the Duravyu programs.Aggiornamento narrativa • Apr 04
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Further Upside
Analysts have lifted EyePoint's implied upside in their models, with recent Street price targets moving from a prior range of about $23 to $31 up to $29 to $35, citing updated estimates after Q4 results, the inclusion of the Phase 3 diabetic macular edema program in valuations, and progress across Duravyu programs. Analyst Commentary Bullish Takeaways Bullish analysts are marking up their price targets into a US$29 to US$35 range, which indicates higher expectations around execution and value creation after the recent Q4 update.Aggiornamento narrativa • Mar 20
EYPT: Phase 3 Diabetic Macular Edema Trials Will Support Further Upside
Narrative Update on EyePoint Analysts have lifted the average price target on EyePoint by about $0.33 to $37.42 as recent research updates incorporate Phase 3 diabetic macular edema expectations and refreshed estimates following the Q4 report. Analyst Commentary Recent research updates on EyePoint focus on refreshed valuation work after the Q4 report and the inclusion of specific pipeline programs in analysts’ models.Aggiornamento narrativa • Mar 06
EYPT: Phase 3 Diabetic Macular Edema Program Will Drive Future Upside
Analysts have raised their average price target for EyePoint to approximately $37 per share, up from about $36. They attribute this change to updated assumptions following the Q4 results, including the integration of the Phase 3 diabetic macular edema program and revised expectations for the Duravyu franchise.Aggiornamento narrativa • Feb 19
EYPT: Rebrand And Refined Profit Outlook Will Support Future Upside
Analysts now set a refreshed price target for EyePoint at $36.08, with the update linked to modest adjustments in the discount rate, profit margin expectations, and future P/E assumptions. What's in the News On December 8, 2025, EyePoint Pharmaceuticals, Inc.Articolo di analisi • Feb 04
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
The EyePoint, Inc. ( NASDAQ:EYPT ) share price has softened a substantial 27% over the previous 30 days, handing back...Aggiornamento narrativa • Jan 19
EYPT: Phase 3 Safety Progress And Rebrand Will Support Future Upside
Analysts have raised their price target on EyePoint to reflect updated assumptions on profit margin and future P/E. The new target is now approximately $36.08 per share.Aggiornamento narrativa • Jan 05
EYPT: Recent Capital Raise And Lock Ups Will Support Future Upside
Analysts have slightly raised their price target on EyePoint to US$36.08, with the modest adjustment tied to unchanged fair value assumptions and very small tweaks to inputs like discount rate, revenue growth, profit margin and future P/E expectations. What's in the News EyePoint Pharmaceuticals, Inc.Aggiornamento narrativa • Dec 20
EYPT: Phase 3 Ocular Trial Progress Will Drive Future Upside Potential
Analysts have raised their price target on EyePoint from approximately $34.42 to $36.08 per share. This reflects increased confidence in the company’s significantly higher projected revenue growth, despite a modestly higher discount rate and slightly lower forecast profit margins and future valuation multiples.Articolo di analisi • Dec 12
After Leaping 38% EyePoint, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
EyePoint, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a great month, posting...Articolo di analisi • Sep 06
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...Aggiornamento narrativa • Aug 15
Phase III Trials In Wet AMD Will Expand Market Reach
EyePoint Pharmaceuticals’ consensus price target remained unchanged at $34.42, as strong Phase 2 data and operational improvements offset in-line clinical progress in the development of Duravyu. Analyst Commentary Completion of enrollment in the second Phase 3 LUCIA study for Duravyu.Articolo di analisi • Jun 16
After Leaping 47% EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Are Not Flying Under The Radar
The EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has done very well over the last month, posting an...Articolo di analisi • May 03
Is EyePoint Pharmaceuticals (NASDAQ:EYPT) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Nuova narrativa • Mar 27
DURAVYU Phase III Trials Will Accelerate Market Entry
Expedited Phase III trial progress and robust patent protection could maximize long-term revenue and margin potential for DURAVYU.Articolo di analisi • Mar 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year
Shareholders of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) will be pleased this week, given that the stock price is...Articolo di analisi • Feb 26
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Summary EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ongoing Phase 3 studies suggest significant upside potential, though past mixed results and heavy competition raise risks. Recent fundraising and a new manufacturing facility indicate strong commitment, but the company's financial health and market skepticism remain concerns. I maintain a "risky buy" rating, believing in the potential for substantial gains if pivotal studies succeed, despite the inherent risks and competition. Read the full article on Seeking AlphaArticolo di analisi • Dec 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 29% after a relatively good...Seeking Alpha • Nov 14
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Summary EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME, with one phase 3 trial ongoing and one more planned for 2025. EYP-1901 demonstrated strong safety, and efficacy, and reduced treatment burden, positioning it as a potential long-term solution for retinal diseases. Despite a failed NPDR trial, positive DME data suggest potential for targeting more severe diabetic retinopathy, enhancing the investment thesis. EyePoint's financials are robust with a cash runway into 2027, but risks include phase 3 trial outcomes and competition from entrenched anti-VEGF therapies. Read the full article on Seeking AlphaArticolo di analisi • Oct 29
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a really impressive month, gaining 52% after a shaky...Articolo di analisi • Sep 13
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Key Insights The projected fair value for EyePoint Pharmaceuticals is US$12.22 based on 2 Stage Free Cash Flow to...Seeking Alpha • Aug 29
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Summary EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains. Despite risks, I upgrade EyePoint to "Buy" due to potential price volatility and multiple upcoming data catalysts that could drive significant gains. Read the full article on Seeking AlphaArticolo di analisi • Aug 15
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) - they aren't optimistic...Articolo di analisi • Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
As you might know, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) last week released its latest second-quarter, and...Articolo di analisi • Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Unfortunately for some shareholders, the EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) share price has dived 27% in...Seeking Alpha • May 06
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
Summary EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an NPDR trial, failing its primary endpoint. Financially, EyePoint is sound with a healthy current ratio and sufficient cash runway, yet facing significant future costs. Investment recommendation: Downgrade EYPT to "Sell" due to high risks and competitive pressures, despite some positive trial results. Read the full article on Seeking AlphaArticolo di analisi • Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 26% after a relatively good...Seeking Alpha • Feb 20
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Summary EyePoint Pharmaceuticals' EYP-1901 drug for wet AMD showed positive results in Phase 2 clinical trials, potentially offering a lower-cost and more effective treatment option. The company's proprietary Durasert E technology delivers drugs directly to the eye, maximizing efficacy and minimizing side effects. The company's financials show a decent cash runway, but with high cash burn and premium valuation, financial stability is a concern. Despite promising technology and pipeline, EyePoint Pharmaceuticals' high valuation suggests its stock's potential upside is already reflected in the price. Therefore, I think EYPT is a "hold" for now. Read the full article on Seeking AlphaArticolo di analisi • Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Despite an already strong run, EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have been powering on, with a gain...Articolo di analisi • Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, EyePoint Pharmaceuticals fair value estimate is US$36.54...Rendimenti per gli azionisti
| EYPT | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | -9.4% | 0.9% | -0.1% |
| 1Y | -71.2% | 48.1% | 11.9% |
Ritorno vs Industria: EYPT ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 48.1 % nell'ultimo anno.
Rendimento vs Mercato: EYPT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 11.9 % nell'ultimo anno.
Volatilità dei prezzi
| EYPT volatility | |
|---|---|
| EYPT Average Weekly Movement | 22.7% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EYPT è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di EYPT è aumentata da 14% a 23% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2000 | 214 | Jay Duker | eyepoint.bio |
EyePoint, Inc. è impegnata nello sviluppo e nella commercializzazione di farmaci per migliorare la vita dei pazienti affetti da gravi malattie della retina. La pipeline dell'azienda sfrutta la tecnologia bioerodibile Durasert E, di sua proprietà, per la somministrazione sostenuta di farmaci intraoculari. Il suo candidato principale è DURAVYU, un trattamento sperimentale a rilascio prolungato per le malattie retiniche mediate dal fattore di crescita endoteliale vascolare che combina vorolanib, un inibitore tirosin-chinasico selettivo e protetto da brevetto, con Durasert E, che è in fase 3 di sperimentazione clinica per la degenerazione maculare senile umida (AMD umida) e l'edema maculare diabetico (DME).
EyePoint, Inc. Riepilogo dei fondamenti
| EYPT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$331.92m |
| Utili (TTM) | -US$306.64m |
| Ricavi(TTM) | US$2.79m |
119.1x
Rapporto P/S-1.1x
Rapporto P/EEYPT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EYPT Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.79m |
| Costo del fatturato | US$260.26m |
| Profitto lordo | -US$257.47m |
| Altre spese | US$49.17m |
| Utili | -US$306.64m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -3.56 |
| Margine lordo | -9,235.01% |
| Margine di profitto netto | -10,998.67% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato EYPT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 08:20 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
EyePoint, Inc. è coperta da 24 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |